IGM BIOSCIENCES INC (IGMS)
US4495851085 - Common Stock
IGM Biosciences Announces Refocusing of Sanofi Collaboration
Agreement focuses on immunology/inflammation, aligning with Sanofi’s ongoing commitment to advancing therapies for patients across multiple inflammatory diseases
IGM Biosciences Enters Oversold Territory (IGMS)
IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum
IGM Biosciences to Present at the Stifel 2024 Virtual Targeted Oncology Forum
MOUNTAIN VIEW, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and...
Commit To Buy IGM Biosciences At $5, Earn 17.8% Annualized Using Options
Commit To Buy IGM Biosciences At $5, Earn 21.6% Annualized Using Options
IGM Biosciences (IGMS) Shares Cross Below 200 DMA
IGMS Stock Earnings: IGM Biosciences Beats EPS, Misses Revenue for Q4 2023
IGMS stock results show that IGM Biosciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
IGMS Stock Earnings: IGM Biosciences Beats EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips IGM Biosciences (NASDAQ:IGMS) just reported results for the fourth quarter of 2...
IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
IGM Biosciences Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
MOUNTAIN VIEW, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and...
RBC Capital upgrades IGM Biosciences to outperform (NASDAQ:IGMS)
RBC Capital Markets has upgraded IGM Biosciences (IGMS) to outperform, stating that it saw the company pivoting to becoming a “key” player in the autoimmune the
IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and...
Commit To Buy IGM Biosciences At $7.50, Earn 38.6% Annualized Using Options
Medivir says IGM Biosciences cutbacks won't impact lead product fostrox (OTCMKTS:MVRBF)
Medivir (MVRBF) said that partner IGM Biosciences (IGMS) decision to end some of its drug programs won't impact Medivir's lead program for fostrox. Read more here.
Medivir to present at the Carlsquare Equity Research Investor Day
/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...
IGM Biosciences to cut 22% of workforce, shut down blood cancer programs (NASDAQ:IGMS)
IGM Biosciences (IGMS) said it was slashing around 22% of its workforce as it shuts down its hematologic oncology programs to focus on colorectal cancer and autoimmune diseases.
IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension
IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension
– Priorities: clinical development of DR5 agonist in colorectal cancer and T cell engagers in autoimmune disease – – Plans to file IND for IGM-2644 (CD38...
Bulletin from Extraordinary General Meeting in Medivir AB (publ)
/PRNewswire/ -- Today on 1 December 2023, Medivir AB (publ) (the "Company") held an extraordinary general meeting in Stockholm, whereby the resolution below...
Medivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCC
/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...
Medivir to present at the Redeye Life Science Day
/PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...
Medivir to present at the Erik Penser Bank Company Event
/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...